Susquehanna International Group
ADMA icon

Susquehanna International Group’s ADMA Biologics ADMA Stock Holding History

Susquehanna International Group’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.2M Sell
1,240,200
-321,900
-21% -$5.08M ﹤0.01% 2944
2025
Q4 		$28.5M Buy
1,562,100
+489,700
+46% +$8.25M ﹤0.01% 1866
2025
Q3 		$15.7M Buy
1,072,400
+141,800
+15% +$2.43M ﹤0.01% 2460
2025
Q2 		$16.9M Buy
930,600
+109,300
+13% +$2.23M ﹤0.01% 2179
2025
Q1 		$16.3M Sell
821,300
-59,700
-7% -$1.03M ﹤0.01% 1947
2024
Q4 		$15.1M Buy
881,000
+313,600
+55% +$5.9M ﹤0.01% 2157
2024
Q3 		$11.3M Buy
567,400
+154,100
+37% +$2.4M ﹤0.01% 2452
2024
Q2 		$4.62M Buy
413,300
+351,600
+570% +$2.95M ﹤0.01% 3568
2024
Q1 		$407K Buy
61,700
+14,900
+32% +$81.4K ﹤0.01% 8993
2023
Q4 		$212K Sell
46,800
-2,600
-5% -$9.62K ﹤0.01% 10570
2023
Q3 		$177K Sell
49,400
-45,800
-48% -$176K ﹤0.01% 10366
2023
Q2 		$351K Buy
95,200
+4,900
+5% +$18.2K ﹤0.01% 9117
2023
Q1 		$299K Buy
90,300
+11,200
+14% +$38.7K ﹤0.01% 9726
2022
Q4 		$307K Sell
79,100
-51,800
-40% -$160K ﹤0.01% 9045
2022
Q3 		$318K Buy
130,900
+42,500
+48% +$102K ﹤0.01% 9642
2022
Q2 		$175K Buy
88,400
+2,700
+3% +$5.31K ﹤0.01% 10831
2022
Q1 		$157K Buy
85,700
+62,400
+268% +$97.3K ﹤0.01% 11512
2021
Q4 		$33K Sell
23,300
-11,900
-34% -$15.6K ﹤0.01% 12713
2021
Q3 		$40K Sell
35,200
-17,100
-33% -$24K ﹤0.01% 12415
2021
Q2 		$84K Sell
52,300
-12,600
-19% -$22.2K ﹤0.01% 12153
2021
Q1 		$114K Buy
64,900
+21,100
+48% +$48.3K ﹤0.01% 11789
2020
Q4 		$85K Sell
43,800
-84,900
-66% -$178K ﹤0.01% 10574
2020
Q3 		$308K Buy
+128,700
New +$353K ﹤0.01% 8647
2020
Q2 		– Sell
-20,100
Closed -$58K – 10035
2020
Q1 		$58K Buy
+20,100
New +$69.5K ﹤0.01% 9603
2019
Q3 		– Sell
-15,600
Closed -$60K – 10086
2019
Q2 		$60K Sell
15,600
-17,500
-53% -$77.2K ﹤0.01% 9794
2019
Q1 		$125K Buy
+33,100
New +$117K ﹤0.01% 8155

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Susquehanna International Group's ADMA Position: Q1 2026 in Review

Susquehanna International Group increased its ADMA Biologics (ADMA) stake by 2,882% in Q1 2026, buying an estimated $15.6M and bringing the position to 1,021,604 shares worth $9.2M. The position accounts for ﹤0.01% of the portfolio, ranked #3239.

Susquehanna International Group first reported a position in ADMA in Q1 2015 and has held it in 31 quarters since. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Susquehanna International Group held 1,021,604 shares of ADMA Biologics worth $9.2M as of Q1 2026.
  • Susquehanna International Group bought 987,349 ADMA Biologics shares in Q1 2026, an estimated $15.6M.
  • ADMA Biologics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #3239 holding.
  • Susquehanna International Group first reported a position in ADMA Biologics in Q1 2015 and has held it in 31 quarters since.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.